These results can be attributed to the expression of NMB glycoprotein, which is much higher on the surface of TNBC cancer cells than on HER-2-positive ones [82], suggesting the potential use of glembatumumab-vedotin for TNBC therapy. The gene discussed is ERBB2; the disease is cancer.